false
Catalog
Opioids Overview: Hope for Our Future
Opioids Overview: Hope for Our Future
Opioids Overview: Hope for Our Future
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video discusses the ongoing opioid epidemic and its impact on American Indian and Alaska Native communities. Over 107,000 Americans died from drug overdoses in 2021, with opioids being the main cause. Stigma surrounding addiction hinders effective treatment and support, and person-first language is important in combating this stigma. Opioids act on the brain and spinal cord, providing pain relief and euphoria, but also leading to respiratory failure and death in overdose situations. Long-term opioid use can result in dependence, withdrawal symptoms, and addiction. Medications like buprenorphine and methadone can effectively treat opioid use disorder. There have been improvements in addressing the opioid crisis and increasing access to treatment. Dr. Anna Lembke presents in the video, explaining the complexities of addiction and how delay in onset of drug use can lower the risk. She defines addiction as a treatable chronic medical disease influenced by brain circuits, genetics, environment, and life experiences. She compares addiction to other chronic diseases and emphasizes the need to challenge the stigma surrounding addiction treatment. Dr. Lembke discusses the three FDA-approved medications for opioid use disorder - methadone, buprenorphine, and naltrexone - and their effectiveness in reducing deaths, diseases, and violent crimes. She addresses misconceptions and stigma surrounding medication-assisted treatment. Cultural practices and traditions should be integrated into addiction treatment programs for Native communities, and healthcare providers should offer hope and culturally meaningful strategies for prevention and treatment.
Keywords
opioid epidemic
American Indian
Alaska Native
drug overdoses
stigma
addiction
person-first language
respiratory failure
dependence
withdrawal symptoms
buprenorphine
methadone
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.
Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 and grant no. 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
PCSS-MOUD
PCSS-MOUD.org
pcss@aaap.org
8-Hour DEA Training Inquiries, email
PCSS-MOUD
.
ORN
opioidresponsenetwork.org
×
Please select your language
1
English